# NCT04118855 (NCT04118855)

> Toripalimab Combined With Axitinib as Neoadjuvant Therapy in Patients With Non-metastatic Locally Advanced Nonmetastatic Clear Cell Renal Cell Carcinoma

No report yet. It can be ordered.

- Drugs tested: toripalimab plus axitinib
- Indication: locally advanced nonmetastatic clear cell renal cell carcinoma

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04118855
- Phase: PHASE2
- Status: COMPLETED
- Sponsor: RenJi Hospital
- Conditions: Neoadjuvant Therapy of Non-metastatic Locally Advanced Renal Cell Carcinoma
- Interventions: Toripalimab; Axitinib
- Enrollment: 20
- Primary outcome: Objective Tumor Response Rate

## Indexed commentary on NCT04118855 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 3 posts on X

## Order

Focused, $750 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=nct04118855